Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $20.89 Consensus Target Price from Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has been assigned a consensus recommendation of “Buy” from the ten ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, seven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price target among brokers that have covered the stock in the last year is $20.89.

A number of analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating on shares of Y-mAbs Therapeutics in a report on Wednesday, December 11th. Oppenheimer began coverage on Y-mAbs Therapeutics in a report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price objective for the company. Wedbush reissued an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Brookline Capital Management began coverage on Y-mAbs Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, September 9th.

Y-mAbs Therapeutics Price Performance

Shares of YMAB stock opened at $8.28 on Monday. The business has a 50-day moving average of $12.36 and a 200 day moving average of $12.57. Y-mAbs Therapeutics has a 1-year low of $6.10 and a 1-year high of $20.90. The stock has a market capitalization of $370.85 million, a PE ratio of -15.33 and a beta of 0.61.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $18.46 million during the quarter, compared to the consensus estimate of $23.38 million. During the same quarter in the prior year, the business posted ($0.18) EPS. Analysts anticipate that Y-mAbs Therapeutics will post -0.66 EPS for the current year.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Institutional investors have recently modified their holdings of the business. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Y-mAbs Therapeutics during the 3rd quarter valued at about $44,000. China Universal Asset Management Co. Ltd. boosted its holdings in Y-mAbs Therapeutics by 66.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 8,572 shares of the company’s stock worth $113,000 after purchasing an additional 3,416 shares during the last quarter. Intech Investment Management LLC bought a new stake in Y-mAbs Therapeutics in the 3rd quarter worth approximately $133,000. SG Americas Securities LLC bought a new stake in Y-mAbs Therapeutics in the 3rd quarter worth approximately $178,000. Finally, Empire Financial Management Company LLC purchased a new stake in Y-mAbs Therapeutics during the 3rd quarter valued at $210,000. 70.85% of the stock is owned by hedge funds and other institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.